Esperion Therapeutics
ESPR
$2.18
Share price
4.07%
Change (1 day)
59.93%
Change (1 year)
Categories
P/S ratio for Esperion Therapeutics (ESPR)
P/S ratio as of June 2024 (TTM): 1.72
According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.72356. At the end of 2023 the company had a P/S ratio of 2.92.
P/S ratio history for Esperion Therapeutics from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.92 | -51.95% |
| 2022 | 6.08 | 56.69% |
| 2021 | 3.88 | 31.08% |
| 2020 | 2.96 | -73.21% |
| 2019 | 11.1 | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.88 | 67.03% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 9.01 | 422.75% | 🇺🇸 USA |
 Ultragenyx RARE | 8.15 | 373.13% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | 266 | 15,328.42% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | 6.90 | 300.53% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 6.53 | 278.73% | 🇺🇸 USA |